[go: up one dir, main page]

SI2438048T1 - Policiklični antagonisti lizofosfatidičnih kislinskih receptorjev - Google Patents

Policiklični antagonisti lizofosfatidičnih kislinskih receptorjev

Info

Publication number
SI2438048T1
SI2438048T1 SI201030496T SI201030496T SI2438048T1 SI 2438048 T1 SI2438048 T1 SI 2438048T1 SI 201030496 T SI201030496 T SI 201030496T SI 201030496 T SI201030496 T SI 201030496T SI 2438048 T1 SI2438048 T1 SI 2438048T1
Authority
SI
Slovenia
Prior art keywords
lysophosphatidic acid
acid receptors
polycyclic
antagonists
polycyclic antagonists
Prior art date
Application number
SI201030496T
Other languages
English (en)
Inventor
John Howard Hutchinson
Thomas Jon Seiders
Bowei Wang
Jeannie M. Arruda
Jeffrey Roger Roppe
Timothy Parr
Original Assignee
Amira Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amira Pharmaceuticals, Inc. filed Critical Amira Pharmaceuticals, Inc.
Publication of SI2438048T1 publication Critical patent/SI2438048T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
SI201030496T 2009-06-03 2010-06-03 Policiklični antagonisti lizofosfatidičnih kislinskih receptorjev SI2438048T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18378509P 2009-06-03 2009-06-03
EP10784122.3A EP2438048B1 (en) 2009-06-03 2010-06-03 Polycyclic antagonists of lysophosphatidic acid receptors
PCT/US2010/037309 WO2010141761A2 (en) 2009-06-03 2010-06-03 Polycyclic antagonists of lysophosphatidic acid receptors

Publications (1)

Publication Number Publication Date
SI2438048T1 true SI2438048T1 (sl) 2014-04-30

Family

ID=42471045

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201030496T SI2438048T1 (sl) 2009-06-03 2010-06-03 Policiklični antagonisti lizofosfatidičnih kislinskih receptorjev

Country Status (28)

Country Link
US (2) US8058300B2 (sl)
EP (1) EP2438048B1 (sl)
JP (1) JP5599457B2 (sl)
KR (2) KR101774722B1 (sl)
CN (2) CN105061346A (sl)
AU (2) AU2010256501B2 (sl)
BR (1) BRPI1014582A2 (sl)
CA (1) CA2764445C (sl)
CL (1) CL2011003072A1 (sl)
CO (1) CO6480918A2 (sl)
DK (1) DK2438048T3 (sl)
EA (1) EA020139B1 (sl)
ES (1) ES2445714T3 (sl)
GB (1) GB2470833B (sl)
HR (1) HRP20140036T1 (sl)
IL (2) IL216220A (sl)
MX (1) MX2011012839A (sl)
MY (1) MY163055A (sl)
NZ (1) NZ596826A (sl)
PE (1) PE20120936A1 (sl)
PL (1) PL2438048T3 (sl)
PT (1) PT2438048E (sl)
SG (1) SG176112A1 (sl)
SI (1) SI2438048T1 (sl)
SM (1) SMT201400031B (sl)
TW (1) TWI405757B (sl)
WO (2) WO2010141761A2 (sl)
ZA (1) ZA201108421B (sl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010068775A2 (en) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
MX2012003560A (es) * 2009-09-25 2012-10-05 Astellas Pharma Inc Compuesto de amida sustituida.
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
US20120267025A1 (en) * 2009-12-11 2012-10-25 Guido Luigi Daghini Tyre for a wheel of a heavy load vehicle
HRP20180970T1 (hr) 2010-12-07 2018-08-10 Amira Pharmaceuticals, Inc. Policiklični lpa1 antagonist i njegove primjene
US8541587B2 (en) 2011-04-05 2013-09-24 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists
AU2012296662A1 (en) * 2011-08-15 2014-03-27 Intermune, Inc. Lysophosphatidic acid receptor antagonists
WO2013070879A1 (en) * 2011-11-10 2013-05-16 Bristol-Myers Squibb Company Methods for treating spinal cord injury with lpa receptor antagonists
BR112014012288A2 (pt) 2011-11-22 2017-05-23 Intermune Inc métodos para diagnosticar e tratar fibrose pulmonar idiopática
PE20142445A1 (es) * 2012-06-20 2015-01-28 Hoffmann La Roche Compuestos de pirazol sustituidos como antagonistas de lpar
BR112014030685A2 (pt) * 2012-06-20 2017-06-27 Hoffmann La Roche compostos de n-alquiltriazol como antagonistas de lpar
EP2925728A4 (en) * 2012-11-27 2016-11-02 Glaxosmithkline Llc COMBINATION
DK3360869T3 (da) 2012-12-28 2020-10-12 Ube Industries Halogen-substitueret heterocyklisk forbindelse anvendelig til behandlingen af sygdomme forårsaget af lpa.
US20140213538A1 (en) * 2013-01-15 2014-07-31 Intermune, Inc. Lysophosphatidic acid receptor antagonists
DK2988743T3 (da) 2013-03-15 2021-03-01 Epigen Biosciences Inc Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
US9987381B2 (en) * 2013-10-31 2018-06-05 Bristol-Myers Squibb Company Radioligands for imaging the LPA-1 receptor
AU2015281021B9 (en) 2014-06-27 2019-03-28 Ube Corporation Salt of halogen-substituted heterocyclic compound
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
TWI770157B (zh) * 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
EP3609869A1 (de) * 2017-04-10 2020-02-19 Bayer Aktiengesellschaft Substituierte n-arylethyl-2-arylchinolin-4-carboxamide und ihre verwendung
US20200215085A1 (en) * 2017-07-19 2020-07-09 Uti Limited Partnership Method to Abate Acute Airway Hypersensitivity and Asthma Attacks
CA3082108A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
WO2019099294A1 (en) 2017-11-14 2019-05-23 Merck Sharp & Dohme Corp. Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
WO2019126099A1 (en) 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole n-linked carbamoyl cyclohexyl acids as lpa antagonists
KR20210010635A (ko) * 2018-06-18 2021-01-27 에피젠 바이오싸이언시즈, 아이엔씨. 질환의 치료에 유용한 헤테로환식 화합물
CN113473985A (zh) 2018-09-18 2021-10-01 百时美施贵宝公司 作为lpa拮抗剂的环戊酸
CN114599641A (zh) * 2019-06-18 2022-06-07 百时美施贵宝公司 作为lpa拮抗剂的环丁基羧酸
EP3986552B1 (en) * 2019-06-18 2024-09-18 Bristol-Myers Squibb Company Isoxazole carboxylic acids as lpa antagonists
EP3986551B1 (en) * 2019-06-18 2025-10-29 Bristol-Myers Squibb Company Triazole carboxylic acids as lpa antagonists
CN119823001A (zh) 2019-07-30 2025-04-15 大正制药株式会社 拮抗lpa1受体的脲化合物
EP4058144A1 (en) 2019-11-15 2022-09-21 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
EP4069227A1 (en) 2019-12-04 2022-10-12 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
KR102393079B1 (ko) 2020-02-28 2022-04-29 한국화학연구원 가축 호흡기 질환의 예방 또는 치료용 조성물
TWI838626B (zh) 2020-06-03 2024-04-11 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
US11702407B2 (en) 2020-06-03 2023-07-18 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
US12383547B2 (en) 2020-07-01 2025-08-12 Vanderbilt University Methods of treatment for a kidney disease
WO2022100625A1 (zh) * 2020-11-10 2022-05-19 武汉人福创新药物研发中心有限公司 氮取代氨基碳酸酯噻吩类化合物及其用途
CN117295717A (zh) 2021-05-11 2023-12-26 吉利德科学公司 Lpa受体拮抗剂及其用途
US11939318B2 (en) 2021-12-08 2024-03-26 Gilead Sciences, Inc. LPA receptor antagonists and uses thereof
KR20250120435A (ko) 2022-12-23 2025-08-08 브리스톨-마이어스 스큅 컴퍼니 간질성 폐 질환을 치료하기 위한 lpa1 길항제
WO2024249867A1 (en) * 2023-06-02 2024-12-05 Am Sciences Compounds for treating fibrotic diseases

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE69720773T2 (de) 1996-12-23 2004-01-29 Bristol Myers Squibb Pharma Co SAUERSTOFF ODER SCHWEFEL ENTHALTENDE 5-GLIEDRIGE HETEROAROMATISHE DERIVATIVE ALS FACTOR Xa HEMMER
JP3237608B2 (ja) 1997-04-21 2001-12-10 住友製薬株式会社 イソキサゾール誘導体
ES2197092T3 (es) 1999-04-02 2004-01-01 Bristol-Myers Squibb Pharma Company Sulfonil arilos como inhibidores del factor xa.
EP1258484B1 (en) 2000-02-18 2009-01-14 Kyowa Hakko Kirin Co., Ltd. Novel isoxazole and thiazole compounds and use thereof as drugs
AU2001273040A1 (en) 2000-06-27 2002-01-08 Du Pont Pharmaceuticals Company Factor xa inhibitors
ATE447970T1 (de) * 2001-02-08 2009-11-15 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
CN1509178A (zh) * 2001-04-25 2004-06-30 碧欧塞根公司 一种包括溶血磷脂酸的药用组合物
JPWO2003007991A1 (ja) * 2001-07-17 2004-11-04 小野薬品工業株式会社 Ｌｐａ受容体調節剤からなる膵液分泌制御剤
MY151199A (en) * 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
AU2002367129A1 (en) * 2001-12-25 2003-07-15 Ajinomoto Co., Inc. Organ fibrosis inhibitors
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
US20050101518A1 (en) * 2002-01-18 2005-05-12 David Solow-Cordero Methods of treating conditions associated with an EDG-2 receptor
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
US20040014662A1 (en) * 2002-05-08 2004-01-22 Per Lindquist Modulation of neural stem cells and neural progenitor cells
CA2484233A1 (en) 2002-05-13 2003-11-27 Eli Lilly And Company Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
EP1533294A4 (en) * 2002-05-28 2007-07-04 Ono Pharmaceutical Co BETA-ALANINE DERIVATIVE AND USE THEREOF
TW200400930A (en) * 2002-06-26 2004-01-16 Ono Pharmaceutical Co Therapeutic agent for chronic disease
US7820682B2 (en) * 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
US20040171037A1 (en) * 2002-11-19 2004-09-02 Jing Li Amplified genes involved in cancer
US20040167132A1 (en) * 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associted with an Edg-2 receptor
US20050065194A1 (en) * 2003-01-16 2005-03-24 Geetha Shankar Methods of treating conditions associated with an Edg-2 receptor
US20040192739A1 (en) * 2003-01-16 2004-09-30 David Solow-Cordero Methods of treating conditions associated with an Edg-2 receptor
US7135469B2 (en) * 2003-03-18 2006-11-14 Bristol Myers Squibb, Co. Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors
KR20060025132A (ko) 2003-04-11 2006-03-20 더 유니버시티 오브 테네시 리서치 파운데이션 리소포스파티드산 유사체 및 신생내막 형성의 저해
US7115642B2 (en) * 2003-05-02 2006-10-03 Rigel Pharmaceuticals, Inc. Substituted diphenyl isoxazoles, pyrazoles and oxadiazoles useful for treating HCV infection
WO2005012269A1 (ja) * 2003-08-05 2005-02-10 Ajinomoto Co., Inc. 新規アゾール化合物
WO2005032494A2 (en) 2003-10-09 2005-04-14 University Of Tennessee Research Foundation Lpa receptor agonists and antagonists and methods of use
US7875745B2 (en) 2003-12-19 2011-01-25 Ono Pharmaceutical Co., Ltd. Compounds having lysophosphatidic acid receptor antagonism and uses thereof
DE10360369A1 (de) * 2003-12-22 2005-07-14 Bayer Cropscience Ag Amide
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
JP2006096712A (ja) 2004-09-30 2006-04-13 Senju Pharmaceut Co Ltd Ｌｐａ受容体拮抗剤を含有する角膜知覚改善剤
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2006133559A1 (en) * 2005-06-14 2006-12-21 Merck Frosst Canada Ltd. Reversible inhibitors of monoamine oxidase a and b
WO2007007588A1 (ja) 2005-07-08 2007-01-18 Ono Pharmaceutical Co., Ltd. 平面性を有する環状基を母核とする化合物
RU2008110949A (ru) 2005-08-23 2009-09-27 Айрм Ллк (Bm) Соединения и композиции-иммуносупрессанты
EP2013176A2 (en) * 2006-02-27 2009-01-14 Sterix Limited Diaryl compounds as non-steroidal inhibitors of 17-beta hydroxysteroid dehydrogenase and/or steroid sulphatase for the treatment of oestrogen-related diseases such as hormone dependent breast cancer
US20090029949A1 (en) 2006-05-25 2009-01-29 Parrill-Baker Abby L GPCR Ligands Identified by Computational Modeling
JP2009545531A (ja) 2006-07-24 2009-12-24 ユニバーシティ オブ バージニア パテント ファンデーション ホスホン酸ビニルリゾホスファチジン酸受容体拮抗薬
WO2008024979A2 (en) 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
US20080051372A1 (en) * 2006-08-24 2008-02-28 The Scripps Research Institute Methods utilizing cell-signaling lysophospholipids
AU2007334436A1 (en) * 2006-12-15 2008-06-26 Abbott Laboratories Novel oxadiazole compounds
WO2008112201A2 (en) 2007-03-12 2008-09-18 The General Hospital Corporation Lysophosphatidic acid receptor targeting for lung disease
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2009011850A2 (en) 2007-07-16 2009-01-22 Abbott Laboratories Novel therapeutic compounds
EP2303270B1 (en) 2008-05-05 2017-05-17 Sanofi Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
WO2010068775A2 (en) 2008-12-11 2010-06-17 Amira Pharmaceuticals, Inc. Alkyne antagonists of lysophosphatidic acid receptors
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
WO2011017350A2 (en) 2009-08-04 2011-02-10 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
US20130253019A1 (en) 2010-06-15 2013-09-26 John Howard Hutchinson Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists

Also Published As

Publication number Publication date
PE20120936A1 (es) 2012-08-01
GB2470833B (en) 2011-06-01
WO2010141761A3 (en) 2011-04-21
DK2438048T3 (en) 2014-03-17
ZA201108421B (en) 2013-04-24
AU2016202676B2 (en) 2018-02-22
AU2016202676A1 (en) 2016-05-26
KR101774722B1 (ko) 2017-09-04
CN102459204B (zh) 2015-08-12
EP2438048B1 (en) 2013-12-18
EP2438048A2 (en) 2012-04-11
MX2011012839A (es) 2012-04-02
TWI405757B (zh) 2013-08-21
US20120015991A1 (en) 2012-01-19
CA2764445C (en) 2018-01-02
IL216220A (en) 2015-09-24
EA201101709A1 (ru) 2012-06-29
HK1163085A1 (en) 2012-09-07
MY163055A (en) 2017-08-15
US20100311799A1 (en) 2010-12-09
GB2470833A (en) 2010-12-08
GB201009231D0 (en) 2010-07-21
EP2438048A4 (en) 2012-11-07
PL2438048T3 (pl) 2014-05-30
ES2445714T3 (es) 2014-03-04
US8058300B2 (en) 2011-11-15
JP2012528884A (ja) 2012-11-15
NZ596826A (en) 2014-03-28
GB2470833A8 (en) 2011-03-30
AU2010256501A1 (en) 2011-12-22
KR20160068984A (ko) 2016-06-15
IL240749B (en) 2018-07-31
CN105061346A (zh) 2015-11-18
US8273780B2 (en) 2012-09-25
HRP20140036T1 (hr) 2014-02-14
TW201103896A (en) 2011-02-01
CL2011003072A1 (es) 2012-04-27
WO2010141768A3 (en) 2011-03-31
SMT201400031B (it) 2014-05-07
IL240749A0 (en) 2015-10-29
CN102459204A (zh) 2012-05-16
BRPI1014582A2 (pt) 2016-04-26
EA020139B1 (ru) 2014-08-29
JP5599457B2 (ja) 2014-10-01
KR101628706B1 (ko) 2016-06-09
CO6480918A2 (es) 2012-07-16
CA2764445A1 (en) 2010-12-09
SG176112A1 (en) 2011-12-29
WO2010141768A2 (en) 2010-12-09
AU2010256501B2 (en) 2016-04-21
WO2010141761A2 (en) 2010-12-09
KR20120026593A (ko) 2012-03-19
PT2438048E (pt) 2014-02-26
IL216220A0 (en) 2012-01-31

Similar Documents

Publication Publication Date Title
GB2470833B (en) Polycyclic antagonists of lysophosphatidic acid receptors
GB2466121B (en) Antagonists of lysophosphatidic acid receptors
GB2474748B (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) Compounds as Lysophosphatidic acid receptor antagonists
EP2462128A4 (en) COMPOUNDS AS LYSOPHOSPHATIDE ACID RECEPTOR ANAGONISTS
SG2014011555A (en) Lysophosphatidic acid receptor antagonists
GB2461629B (en) Antagonists of prostaglandin D2 receptors
EP2245022A4 (en) ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
PL2927224T3 (pl) Antagoniści receptora
AP3360A (en) Pyrazole compounds as CRTH2 antagonists
EP2310392A4 (en) TRICYCLIC ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
PT2590992T (pt) Análogos agonistas do recetor de opioides mu das endomorfinas
EP2539706A4 (en) ARYLPIPERAZON-OPIOID RECEPTOR ANTAGONISTS
ZA201209495B (en) Novel methods for the preparation of p2x7r antagonists
HK1167860A (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
GB0922455D0 (en) Ep2 receptor antagonists